ClinicalTrials.gg
RecruitingNCT06929533PGx-SUPPORTUpdated Sep 8, 2025

Pharmacogenomics-Supported Psychotropic Prescribing Trial

An interventional study of Pharmacogenetic Testing in Mental Disorder, Pharmacogenetics and Adverse Drug Reaction (ADR), sponsored by University of Manitoba. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by University of Manitoba · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Read the detailed description

Background and Rationale: Pharmacogenomic (PGx) testing utilizes genetic information as a surrogate marker of a person's ability to process and react to drugs. This information can be used to inform medication selection and dosing, reducing the number of trials needed to choose a suitable medicine. For Manitoba healthcare providers, the only access to psychiatric PGx testing is through commercial providers, costing patients $200 to $2,300. To the best of our knowledge, no study in Manitoba has previously evaluated the feasibility of PGx testing in adult patients seeking care for mental illness.

RESEARCH OBJECTIVES: We aim to investigate the feasibility and utility of implementing PGx testing in Manitoba for adult patients seeking care for mental illness.

Primary Outcome and Measures: Feasibility will be measured along four dimensions:

  • Acceptability (satisfaction surveys - patient \& clinician)
  • Practicality (testing turnaround time)
  • Implementation (clinicians' self-reported use of testing results in the prescribing decision-making process)
  • Demand (number of referrals, clinicians' self-reported intent to use testing in the future)

Secondary Outcomes and Measures:

  • Changes in global functioning and symptom severity [Clinical Global Impression (CGI) - Severity and Improvement; Brief Psychiatric Rating Scale (BPRS); DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure; Patient Health Questionnaire-9 (PHQ-9); General Anxiety Disorder-7 (GAD-7); Altman Self-Rating Mania Scale (ASRM); Early Psychosis Screener (EPS-26)]
  • Adverse drug experience [Frequency, Intensity, Burden of Side Effects Rating (FIBSER)]
  • Impact of PGx testing [Changes in medication prescribing and dispensing patterns; changes in healthcare utilization (e.g., inpatient length of stay, mental health resource use, and utilization of healthcare services)

Expected Outcomes: The findings from the proposed study will inform policymakers and facilitate decision-making and priority-setting related to implementing PGx-based psychotropic prescribing policies in Manitoba

02

Conditions studied

  • Mental Disorder
  • Pharmacogenetics
  • Adverse Drug Reaction (ADR)
  • Effectiveness

Keywords

  • Adult
  • Mental Health
  • Psychiatry
  • Pharmacogenetics
  • Depression
  • Anxiety
  • OCD
  • Psychosis
  • Bipolar Disorder
  • mental illness
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older
  • The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated
  • The treating clinician thinks PGx testing can benefit and refers the patient to the study

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to donate saliva samples for genetic analysis
  • History of liver or bone marrow (hematopoietic cell) transplantation
  • PGx testing results are already available
  • No personal health identification number (PHIN) is available
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Pharmacogenetic Testing

    Pharmacogenetic testing panel (CYP2C19, CYP2D6, CYP2B6, CYP3A4, CYP3A5, CYP2C9, CYP4F2, DPYD, HLA-A, HLA-B, NUDT15, SLCO1B1, TPMT, VKORC1, 2C Cluster, UGT1A1)

    Diagnostic Test: Pharmacogenetic Testing

Interventions

  • Diagnostic testPharmacogenetic Testing

    Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.

06

What researchers measure

Primary outcomes

  1. Testing Acceptibility

    Acceptability will be measured via a four-item patient satisfaction survey three months after the testing and a two-item clinician satisfaction survey after discharge. Responses will be recorded on a five-point Likert scale (1 = very dissatisfied to 5 = very satisfied).

    Time frame: 3 months after after baseline.

  2. Implementation Practicality

    Practicality will be measured by the mean and median testing turnaround time (i.e., test ordering to return of results).

    Time frame: Up to 3 Months

  3. Implementation Feasibility

    Implementation will be measured using a two-item clinician self-report questionnaire that asks about using testing results in the prescribing decision-making process. These will be Yes/No questions, with more "yes" responses indicating higher usefulness and interest in using the test in clinical practice.

    Time frame: Patient discharge date [within 3 months of baseline].

  4. Test Demands

    Demand will be measured by the total number of referrals to the study and by a one-item clinician self-report questionnaire asking about intent to use the testing in the future. Responses will be recorded on a five-point Likert scale (1 = very unlikely to 5 = very likely).

    Time frame: Patient discharge date [within 3 months of baseline].

Secondary outcomes

  1. Clinical Global Impression Scale (CGI) - Severity

    1 = normal, 7 = among the most extremely ill

    Time frame: Baseline

  2. Clinical Global Impression Scale (CGI) - Improvement

    Assesses the overall change in the patient's condition compared to baseline, on a 7-point scale (1 = very much improved, 7 = very much worse).

    Time frame: 3 months after baseline.

  3. Brief Psychiatric Rating Scale (BPRS)

    The rater enters a number for each symptom construct, ranging from 1 (not present) to 7 (extremely severe).

    Time frame: Baseline and patient discharge date, within 3 months.

  4. DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure - Adult

    This adult version of the measure consists of 23 questions that assess 13 psychiatric domains, including depression, anger, mania, anxiety, somatic symptoms, suicidal ideation, psychosis, sleep problems, memory, repetitive thoughts and behaviors, dissociation, personality functioning, and substance use. Each item on the measure is rated on a 5-point scale (0=none or not at all; 1=slight or rare, less than a day or two; 2=mild or several days; 3=moderate or more than half the days; and 4=severe or nearly every day).

    Time frame: Baseline and 3 months after baseline.

  5. General Anxiety Disorder-7 (GAD-7)

    This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21. 0-4: minimal anxiety 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety

    Time frame: Baseline and 3 months after baseline.

  6. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 asks patients about the frequency with which they have experienced certain symptoms over the past two weeks, using a four-point scale (0 = "not at all" to 3 = "nearly every day"). The total score, ranging from 0 to 27, indicates the severity of depression, with higher scores suggesting more severe symptoms. Scoring: 0-4: Minimal or no symptoms 5-9: Mild depression 10-14: Moderate depression 15-19: Moderately severe depression 20 or higher: Severe depression

    Time frame: Baseline and 3 months after baseline.

  7. Altman Self-Rating Mania Scale (ASRM) - Adult

    Each item on the measure is rated on a 5-point scale (i.e., 1 to 5) with the response categories having different anchors depending on the item. The ASRM score range from 5 to 25 with higher scores indicating greater severity of manic symptoms.

    Time frame: Baseline and 3 months after baseline.

  8. The Early Psychosis Screener (EPS-26)

    The EPS-26 consists of 26 questions that assess for symptoms and experiences associated with psychosis. A higher score on the EPS-26 suggests a greater likelihood of being at risk for psychosis.

    Time frame: Baseline and 3 months after baseline.

  9. Frequency, Intensity, Burden of Side Effects Rating (FIBSER)

    It measures three dimensions: the frequency of side effects, the intensity of these side effects, and the burden they impose on daily functioning. Each dimension is rated on a Likert scale, ranging from 0 to 6, where higher scores indicate greater severity and difficulty caused by side effects.

    Time frame: Baseline (if applicable) and 3 months after baseline.

  10. Healthcare Utlization

    Changes in healthcare utilization (including inpatient length of stay) will be measured using a ten-item patient self-report mental health resource use questionnaire, medical charts, and administrative data records six months before and after the participant enrolled in the study.

    Time frame: 1 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 41 months is above that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 16, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06929533
Collaborators
University of Calgary, Shared Health Manitoba, Winnipeg Regional Health Authority, Health Sciences Centre, Winnipeg, Manitoba
Responsible party
Abdullah Al Maruf (Assistant Professor, University of Manitoba) — Principal investigator
First posted
Apr 16, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 8, 2025

Study contacts

Abdullah Al Maruf, BPharm, MPharm, PhD
Contact
abdullah.maruf@umanitoba.ca
204-318-2575
Abdullah Al Maruf, PhD, M.Pharm., B.Pharm
principal investigator · University of Manitoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion